M. Lebwohl, “Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial”, J of Skin, vol. 7, no. 2, p. s111, Mar. 2023.